Bangladesh vs Viet Nam: Average cost of multi drug-resistant tuberculosis treatment
Bangladesh
466 constant 2022 US$
in 2024
Viet Nam
458 constant 2022 US$
in 2024
Bangladesh rank
81st
Viet Nam rank
83rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Bangladesh
- Viet Nam
How they compare
Bangladesh currently reports 466 constant 2022 US$ against 458 constant 2022 US$ in Viet Nam, a difference of 8 constant 2022 US$.
Across all 8 years both countries report, Bangladesh has been ahead every year.
Bangladesh ranks 81st and Viet Nam ranks 83rd of 92 countries.
Bangladesh has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bangladesh | Viet Nam | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,374 constant 2022 US$ | 713 constant 2022 US$ | 661 constant 2022 US$ | Bangladesh |
| 2020s | 769 constant 2022 US$ | 570.2 constant 2022 US$ | 198.8 constant 2022 US$ | Bangladesh |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bangladesh or Viet Nam?
- Bangladesh, at 466 constant 2022 US$ against 458 constant 2022 US$ in Viet Nam as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bangladesh and Viet Nam?
- 8 constant 2022 US$, with Bangladesh ahead.
- How many years of comparable data are there for Bangladesh and Viet Nam?
- 8 years are reported by both, from 2017 to 2024.
- How do Bangladesh and Viet Nam rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bangladesh ranks 81st and Viet Nam ranks 83rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.